Full-Time
Clinical Account Manager
Ceribell
201-500 employees
EEG headband device for brain monitoring
Compensation Overview
$100k - $180k/yr
Indiana, USA
In Person
Territory: Northwest Indiana; travel 60% (about 3 days/week); on-site required.
 Sales & Account Management (2) |
|---|
| , |
Get referred to Ceribell
See people who can refer or advise you
- 3-5 years of recent critical care sales experience OR 5 years of medical device or pharma sales experience OR RN’s with industry experience in supporting sales teams
- Launch new hospitals and drive organic growth of install base of hospitals; provide ongoing medical education to physicians and clinical staff using clinical information as foundation for growth.
- Expand use of Ceribell to additional acute or critical care centers within existing customer base.
- Work with the local Territory Manager to launch Ceribell at new customer sites.
- Drive new product and technology introductions for existing customers.
- Build advocacy and champions within facilities; use hospital data to validate and build interest.
- Develop a qualified lead funnel within existing install base; regular activities include formal presentations, peer to peer education, new physician training, and driving physician education.
- Responsible for upgrades and departmental expansion in existing install base.
- Strong project management skill requirement to support new account launches.
- Educate and train physicians, hospital personnel and/or office staff on the merits and proper clinical usage of company products; become a clinical expert in use cases of Ceribell and relevant patient populations.
- Troubleshoot workflow solutions for departments as needs arise.
- Partner with clinicians to identify and establish protocols for patients at risk of seizure.
- Lead clinical teams through training sessions helping understand workflow and applications.
- Submit all required reports and training documentation on a timely basis; use Salesforce.com to manage administrative tasks; ensure compliance with applicable laws, regulations, and Ceribell policies; work cross-functionally to ensure successful deployment of Ceribell products at customer locations; ability to work within a field-based team and strong partnership with Territory Manager.
- Bonus points: start-up experience or experience working with disruptive technology, medical device experience, neuro Intensive Care Unit clinical experience, sales experience
Ceribell makes and sells medical devices that monitor brain activity in hospitals. Its main product is the Ceribell EEG Headband and Recorder, worn by patients and used by trained healthcare providers in clinical settings to collect EEG data. The device captures brain signals and stores them for clinicians to review; it does not diagnose conditions or send automated alerts, leaving interpretation and treatment decisions to physicians. The system is designed for time-sensitive situations, such as Nonconvulsive Status Epilepticus (NCSE), where rapid data can help guide urgent care. Revenue comes from selling the devices to healthcare facilities, with purchases made on physician orders as required by US law. Compared with competitors, Ceribell emphasizes fast, clinician-driven data collection for urgent neurological cases and does not replace clinical judgment with automated diagnoses or alerts.
Company Size
201-500
Company Stage
Series C
Total Funding
$171M
Headquarters
Mountain View, California
Founded
2014
Get referred to Ceribell
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 33% to $28.1 million, and guidance increased to $114 million-$117 million.
- Ceribell won August 2026 FDA clearance for artifact reduction and epileptiform abnormality detection.
- Delirium NTAP reimbursement begins October 1, 2026, supporting commercialization across acute-care hospitals.
What critics are saying
- Natus' ITC case targets Ceribell's core headband patents; a November 19, 2026 ruling threatens imports.
- Q2 growth still relies on existing-hospital utilization, while new indications stay early and multi-month.
- If delirium, pediatric, and stroke launches disappoint, Ceribell remains a single-platform seizure vendor.
What makes Ceribell unique
- Ceribell's five-minute bedside EEG avoids technologists and neurologists, unlike legacy systems.
- Its AI portal trained on one million EEG hours simplifies seizure, delirium, and artifact review.
- 712 hospitals use Ceribell, giving it a deployed clinical workflow moat.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Unlimited Paid Time Off
Paid Holidays
Parental Leave
Annual Bonus Opportunity
Company Equity
Phone/Internet Stipend
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -1%2 year growth
↑ 0%CeriBell expands EEG platform beyond seizures with delirium, pediatric push. August 12, 2026 Key points. * CeriBell is expanding beyond seizure detection into neonatal, pediatric and delirium monitoring, raising its estimated U.S. total addressable market to more than $3.5 billion. A stroke-monitoring product is also in development after receiving FDA breakthrough designation. * The platform is now used in 712 U.S. hospitals, with sales representatives increasing account additions from the mid-20s to the low 30s per quarter. The company is also targeting greater utilization within existing hospitals and multi-hospital health-system deals. * CeriBell plans to launch a new recorder with a camera, larger display, EKG integration and continuous-recording capabilities, while investing in future growth rather than near-term operating leverage. Its litigation with Natus remains active, with a preliminary ITC decision expected in November and a final decision around March 2027. * Five stocks to consider instead of CeriBell. CeriBell NASDAQ: CBLL outlined its plans to expand its brainwave-monitoring platform beyond seizure detection, pointing to new products for delirium, pediatric patients and eventually stroke as it continues to build its hospital customer base. Speaking at Canaccord's 46th Annual Global Growth Conference, Chief Financial Officer Scott Blumberg said the medical technology company is focused on making electroencephalogram, or EEG, monitoring faster and more accessible in emergency departments and intensive care units. Traditional EEG systems can require large equipment as well as specialized technicians and neurologists, resources that may not be readily available in acute-care settings, he said. CeriBell's technology can be set up in about five minutes by trained medical professionals, often nurses, according to Blumberg. The company has paired the hardware with artificial intelligence-powered detection algorithms intended to help bedside clinicians assess neurological conditions in real time. Blumberg said CeriBell's technology has been supported by more than 50 publications and more than 150 publications and abstracts. He said the company's data indicate the platform can support treatment decisions, reduce medication overuse, lower length of stay and reduce patient transfers. The company is currently used in 712 U.S. hospitals, Blumberg said. Its initial focus has been seizure detection in acute care, a market it estimates represents about $2 billion in U.S. total addressable market opportunity. He said the company is roughly 4% penetrated in that core market. Sales force maturation and hospital utilization. Blumberg described CeriBell's commercial organization as having two separate functions: territory managers focused on acquiring new accounts and clinical account managers focused on increasing usage within existing accounts. The company expanded its territory-manager organization from roughly 35 representatives to 55 after its initial public offering. Based on six to seven years of internal history, Blumberg said it generally takes about a year for a territory manager to launch a first account and become productive. He said productivity increases during the second year, when representatives reach their maximum rate of account additions. While CeriBell has raised its account-acquisition pace from the mid-20s to the low 30s accounts per quarter, Blumberg said he expects the rate to continue increasing over time rather than remaining at that level. Discover more EV market analysis Earnings screener tool Stock average calculator He also said the company sees substantial opportunity to increase usage at current hospital customers. CeriBell's technology often replaces EEG monitoring that otherwise would not have been performed because a hospital lacked access to the service, he said. Among hospitals of comparable size, CeriBell's top 10% of accounts conduct roughly three times the monitoring volume of average accounts, according to Blumberg. The company's strategy is to train more doctors, expand into additional hospital departments and incorporate the technology into treatment protocols to encourage more consistent use. New indications, reimbursement and hardware. CeriBell is also expanding the platform into additional patient populations and disease states. Blumberg said the company recently added neonatal and pediatric applications, although he characterized the rollout as still early because activating new departments can be a multi-month sales process. The company has received clearance for a delirium-detection product and is conducting a pilot with a small number of sites, with an intended launch later this year. CeriBell also received favorable Centers for Medicare & Medicaid Services reimbursement through a new technology add-on payment, or NTAP, that provides more than $2,000 per eligible patient, Blumberg said. He said the delirium reimbursement applies to a relatively narrow patient population, including Medicare patients for whom hospitals have negative margins. Blumberg characterized the payment primarily as an "objection handler" that could help hospitals adopt the technology more quickly, rather than as a direct driver of usage. CeriBell is deciding whether delirium will be monetized through a specific charge or through higher platform utilization and demand for additional recorders. Early pilot results, though based on a small sample, have shown usage increases across sites, he said. The company estimates that neonatal, pediatric and delirium applications have increased its U.S. total addressable market to more than $3.5 billion, excluding future indications and markets outside the U.S. For stroke, CeriBell has received an FDA breakthrough designation, though the product remains in development. Blumberg said the company is making steady progress toward an eventual large-vessel-occlusion stroke offering. CeriBell also plans to introduce a new recorder platform and two new disposable products. The new recorder will include a built-in camera, a larger screen, integration with technologies such as EKG, and the ability to plug in and record continuously. Blumberg said the features are intended to support longer-duration monitoring and broader use across seizure, delirium and eventually stroke. Longer-term commercial strategy. In addition to individual hospital sales, CeriBell has created a strategic account manager function aimed at regional health systems. Blumberg said the company has built a pipeline of multi-hospital opportunities involving four to 10 facilities, compared with its more typical one- or two-hospital transactions. He said the initiative could translate into more purchase orders and account additions in 2027, though larger system transactions may move more slowly. Enterprise pricing could also be part of discussions for larger health systems, he said, noting CeriBell has reported 89% gross margins. Blumberg said the company has kept adjusted EBITDA relatively consistent since becoming public, excluding litigation costs, while continuing to invest in sales capacity and product launches. Rather than prioritize near-term operating leverage, he said CeriBell is investing to support growth in 2028, 2029 and beyond while seeking to retain the ability to achieve profitability using cash on hand. Regarding litigation with Natus, Blumberg said a preliminary International Trade Commission decision is scheduled for November, followed by a final decision expected around March 2027. A related Delaware district court case remains stayed, with future timing dependent on the ITC outcome. About CeriBell (NASDAQ:CBLL). CeriBell Corp NASDAQ: CBLL is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention. The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider CeriBell, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list. While CeriBell currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
CeriBell reported Q2 2026 revenue of $28.1 million, up 33% year-over-year, driven by increased utilisation at existing hospitals and new account additions. The company added 32 hospital accounts during the quarter, bringing its total to 712 active accounts. Product revenue rose 33% to $21.2 million, whilst subscription revenue increased 30% to $6.9 million. Chief executive Jane Chao said the quarter marked an acceleration from Q1's 29% growth, extending the company's streak to 33 consecutive quarters of sequential revenue growth. Gross margin reached a record 92%, including $1.6 million in tariff refunds. Excluding this impact, gross margin was 89%. CeriBell raised its full-year revenue outlook and plans to launch its delirium-monitoring solution later this year.
Ceribell has received FDA 510(k) clearance for two AI-powered enhancements to its cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction. These tools aim to improve electroencephalogram (EEG) assessment in critical-care settings. The Artifact Reduction algorithm identifies and filters signal interference from medical equipment and patient movement, simplifying EEG interpretation. The Epileptiform Abnormality Detection feature flags abnormal brain patterns in lengthy recordings, helping neurologists review data more efficiently. The enhancements integrate seamlessly into existing workflows without requiring software downtime or installation. Ceribell's platform, trained on over one million hours of EEG data, reduces the time to initiate bedside monitoring from hours to as few as five minutes. The California-based medical technology company focuses on diagnosing and managing serious neurological conditions through its point-of-care brain monitoring system.
Ceribell receives FDA clearance for advanced Epileptiform Abnormality Detection and Artifact Reduction for its cloud-based portal, delivering greater precision for critical-care EEG review. August 10, 2026 Neurology review software enhancements included as part of industry-leading Ceribell Point-of-Care brain monitoring system. SUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) - CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for two new AI algorithm enhancements integrated directly into its existing cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction.[1] These new capabilities expand the clinical utility of the Ceribell Point-of-Care (POC) brain monitoring system, providing neurologists and bedside practitioners with an enhanced toolset for rapid, high-confidence electroencephalogram (EEG) assessment. Ceribell's new Neurology Portal enhancements introduce AI-driven algorithms designed to tackle two of the biggest hurdles in EEG evaluation: filtering complex background interference and streamlining the review of lengthy, ambiguous brain recordings. Deploying EEGs in fast-paced, critical-care environments, such as emergency departments and intensive care units, is inherently difficult. Non-seizure signal disturbances, or artifacts, originating from nearby medical equipment, patient movement, and other physiological signals, are particularly common. Differentiating these sources of interference from the underlying brain signal can make EEG interpretation challenging and time-consuming, even for well-trained neurologists. Ceribell's new Artifact Reduction algorithm adds a layer of AI-driven sophistication to the existing approach. Beyond the simple filtering employed by most traditional technologies, the new algorithm recognizes and identifies various artifacts based on dedicated training on its own extensive real-world artifact dataset. This significantly simplifies EEG interpretation for neurologists and improves the point-of-care experience. Another common challenge arises during the interpretation of lengthy brain recordings. Reviewing these continuous studies is an intensely time-consuming process because findings do not always fall into a binary "seizure" or "no seizure" distinction. Rather, many brain recordings in critical-care patients show abnormal epileptiform patterns that fall along the ictal-interictal continuum. By analyzing a patient's EEG recordings and flagging these specific epileptiform abnormalities, Ceribell's new technology brings clear structure to this complex clinical gray zone, enabling more timely and precise patient care. Instead of wading through hours of raw data, the reviewing neurologist receives an organized, high-confidence starting point with potential pathology already prominently highlighted in the recording viewer, accelerating their read times and increasing efficiency. "With these new Neurology Portal enhancements, Ceribell continues to push the boundaries of AI innovation in neuromonitoring," said Jane Chao, Ph.D., co-founder and Chief Executive Officer of Ceribell. "This technology directly delivers on critical feedback from clinicians on the front lines. By automatically highlighting epileptiform patterns and isolating non-cerebral artifacts, we give valuable time back to neurologists. This empowers them to make fast, confident bedside decisions when every minute matters." Guided by real-world feedback from clinical users and backed by an expansive database of more than one million hours of EEG data, Ceribell continues to evolve its platform to maximize diagnostic confidence and ease hospital operational burdens. This portal update builds upon the Company's industry-leading POC system, which reduces the time to initiate bedside monitoring from hours to as few as five minutes.[2] The latest enhancements are engineered to seamlessly fit into existing clinical workflows with no software downtime or installation required. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding Ceribell's industry leadership position, the benefits of Ceribell's technology, and continued evolution of the Ceribell platform, are forward-looking statements. Forward-looking statements can be identified by the use of words such as "will," "may," "could," "likely," "ongoing," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "assume," "target," "forecast," "guidance," "goal," "objective," "aim," "seek," "potential," "hope," and other words of similar meaning. These statements are based on management's current expectations and assumptions as of the date of this press release and involve risks and uncertainties that could cause actual results to differ materially from those described. Such risks and uncertainties, including but not limited to those related to regulatory approvals, clinical use and adoption, clinical outcomes, market acceptance, competition, and other factors, are described under the "Risk Factors" sections of the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other reports filed with the U.S. Securities and Exchange Commission ("SEC"). These filings are available on the SEC's website at https://www.sec.gov and on Ceribell's website at https://investors.ceribell.com. Ceribell undertakes no obligation to update any forward-looking statements as a result of new information, future events, or otherwise, except as required by applicable law. About CeriBell, Inc. Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography ("EEG") platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence ("AI")-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit https://www.ceribell.com or follow the company on LinkedIn. Investor Contact Brian Johnston or Caylene Parrish Gilmartin Group [email protected]
Ceribell expands Board of Directors with appointments of Thomas West and Sharon O'Keefe. July 29, 2026 Medtech market-builder Thomas West and health system operator Sharon O'Keefe join Ceribell as point-of-care brain monitoring advances toward standard of care. SUNNYVALE, Calif., July 29, 2026 (GLOBE NEWSWIRE) - CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointments of Thomas "Tom" West and Sharon O'Keefe to its Board of Directors. The new directors bring commercial and health-system leadership experience to the Board as the company expands adoption of its point-of-care brain monitoring platform, now deployed in more than 680 U.S. hospitals. "We are thrilled to welcome Tom and Sharon to our Board," said Rebecca "Beckie" Robertson, chair of the Ceribell Board of Directors. "Tom has spent his career scaling medical technologies from clinical validation to broad commercial adoption and market leadership, and Sharon has led some of the country's largest academic health systems. Their highly complementary experience will be invaluable as Ceribell works to cement its category leadership through innovation and provide greater access to point-of-care brain monitoring." West served as President and Chief Executive Officer of Nalu Medical Inc., a neurostimulation company in the pain space that was acquired by Boston Scientific for $600 million in January of 2026. Previously, he served as President and CEO of Intersect ENT from 2019 to 2022, leading the company through its acquisition by Medtronic for $1.1 billion. Earlier in his career, he served as Worldwide President of Diagnostic Solutions at Hologic and spent more than two decades at Johnson & Johnson, where he led the worldwide diabetes portfolio strategy and business development, and served as Division President of LifeScan North America and Division President of LifeScan EMEA. He also serves as a director on the boards of SI-BONE, Inc., Cyted Health Inc. and ViCentra Inc. and previously served on the boards of Inogen, Inc. and Orthofix Inc. "Ceribell has established a new category in point-of-care brain monitoring, supported by a growing body of clinical evidence and rapid user adoption," said West. "I look forward to working with the board and the management team to help further expand its reach as Ceribell enters its next chapter of growth." O'Keefe most recently served as President of the University of Chicago Medical Center and Chief Operating Officer of the University of Chicago Medicine health system, where she oversaw more than $2 billion in annual operating revenue. She has also served as President of Loyola University Medical Center, Executive Vice President and Chief Operating Officer of Beth Israel Deaconess Medical Center, and Chief Operating Officer of Barnes-Jewish Hospital. In 2013, Modern Healthcare named her one of the 100 Most Influential People in Healthcare. "Health system leaders are increasingly focused on adopting high-value tools that support timely, accurate decisions at the bedside, enable better clinical outcomes, and reduce patient transfer rates. Ceribell's innovative brain monitoring platform aligns perfectly with this goal," said O'Keefe. "I am honored to join Ceribell's board and to contribute to its mission of improving care for patients with serious neurological conditions." _______________________________ Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other statements that are not statements of historical fact. Forward-looking statements can be identified by the use of words such as "will," "may," "could," "likely," "ongoing," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "assume," "target," "forecast," "guidance," "goal," "objective," "aim," "seek," "potential," "hope," and other words of similar meaning. These statements are based on management's current expectations and assumptions as of the date of this press release and involve risks and uncertainties that could cause actual results to differ materially from those described. Such risks and uncertainties, including but not limited to those related to regulatory approvals, clinical use and adoption, clinical outcomes, market acceptance, competition, and other factors, are described under the "Risk Factors" sections of our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other reports filed with the U.S. Securities and Exchange Commission ("SEC"). These filings are available on the SEC's website at https://sec.gov/ and on Ceribell's website at https://investors.ceribell.com/. Ceribell undertakes no obligation to update any forward-looking statements as a result of new information, future events, or otherwise, except as required by applicable law. About CeriBell, Inc. Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography ("EEG") platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence ("AI")-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit http://www.ceribell.com or follow the company on LinkedIn. Investor Contact Brian Johnston or Caylene Parrish Gilmartin Group [email protected]